Benoît van den Eynde
Plus aucun poste en cours
Profil
Benoît van den Eynde was the founder of iTeos Therapeutics SA, which was founded in 2011, where he held the title of Director & Chief Scientific Officer from 2011 to 2013.
Dr. van den Eynde is also the founder of Iteos Belgium SA. He previously worked as a Director at Ludwig Institute for Cancer Research Ltd.
Dr. van den Eynde earned a doctorate degree from University College London.
Anciens postes connus de Benoît van den Eynde
| Sociétés | Poste | Fin |
|---|---|---|
Ludwig Institute for Cancer Research Ltd.
 Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Iteos Belgium SA
 Iteos Belgium SA Pharmaceuticals: MajorHealth Technology Iteos Belgium SA manufactures pharmaceutical raw materials. The private company is based in Gosselies, Belgium. | Fondateur | - |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Fondateur | - |
Formation de Benoît van den Eynde
| University College London | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Ludwig Institute for Cancer Research Ltd.
Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | Health Services |
Iteos Belgium SA
Iteos Belgium SA Pharmaceuticals: MajorHealth Technology Iteos Belgium SA manufactures pharmaceutical raw materials. The private company is based in Gosselies, Belgium. | Health Technology |